Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
Healthcare
$49.56 -0.96%
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
52W Low $32.53High $57.82
Volume 4.26M
Average 2.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$654.33M
FY 2025 · Annual
-2.9% YoYInvesting Cash Flow
-$305.28M
FY 2025 · Annual
Financing Cash Flow
-$178.98M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Depreciation & Amortization | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| Deferred Income Tax | (5.29M) | (9.6M) | 10.73M | (23.04M) | (20.07M) |
| Stock-Based Compensation | 38.39M | 49.51M | 47.1M | 43.63M | 50.4M |
| Change in Working Capital | (130.01M) | (31.88M) | (186.96M) | 135.45M | (34.51M) |
| Accounts Receivables | (7.4M) | 15.45M | (55.12M) | 12.22M | (36.39M) |
| Inventory | (81.8M) | (61.95M) | (44.79M) | 87.76M | (848K) |
| Accounts Payables | (5.98M) | (1.76M) | (22.42M) | 1.45M | (8.42M) |
| Other Working Capital | (34.83M) | 16.37M | (64.64M) | 34.03M | 11.15M |
| Other Non-Cash Items | 8.38M | 75.63M | 41.94M | 230.65M | 39.88M |
| Operating Cash Flow | 639M | 715.26M | 459.46M | 673.55M | 654.33M |
| Capital Expenditures | (206.53M) | (149.34M) | (162.8M) | (167.17M) | (201.05M) |
| Acquisitions (Net) | (16.63M) | (63.65M) | (149.53M) | 0 | (291.23M) |
| Purchases of Investments | (400.3M) | (1.39B) | (979.32M) | (688.38M) | (371.82M) |
| Sales of Investments | 359.56M | 883.08M | 1.27B | 584.98M | 597.06M |
| Other Investing Activities | 61.47M | (9.77M) | (66.55M) | 21.35M | (32.16M) |
| Investing Cash Flow | (202.43M) | (726.76M) | (87.66M) | (249.23M) | (305.28M) |
| Debt Repayment | (41.35M) | (108.55M) | (436.76M) | (107.33M) | 208.15M |
| Common Stock Issued | 7.92M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (99.99M) | (25.36M) | (17.68M) | (292.1M) | (307.36M) |
| Dividends Paid | 0 | 0 | 0 | 0 | (54.24M) |
| Other Financing Activities | (16.95M) | 8.11M | 20.61M | (23.47M) | (25.53M) |
| Financing Cash Flow | (150.37M) | (125.8M) | (433.83M) | (422.9M) | (178.98M) |
| Effect of Forex Changes | (3.68M) | (12.55M) | (558K) | (5.96M) | 5.38M |
| Net Change in Cash | 282.53M | (149.85M) | (62.59M) | (4.53M) | 175.45M |
| Free Cash Flow | 432.47M | 565.93M | 296.65M | 506.38M | 453.28M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$424.9M
+ D&A$193.7M
+ Stock-Based Comp$50.4M
- Deferred Tax-$20.1M
- Working Capital-$34.5M
+ Other Non-Cash$39.9M
= Operating Cash Flow$654.3M
- Capex-$201.0M
= Free Cash Flow$453.3M
Analysis
FY2025 free cash flow is $453.3M. FCF conversion is 106.7% of net income. Operating cash flow was $654.3M, with capex of -$201.0M. The largest bridge item is Capex at -$201.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Nov 6, 2026 | |
| SC TO-C | SC TO-C filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Oct 23, 2026 |
Does QGEN generate free cash flow?
Qiagen N.V. (QGEN) generated $453.28M of free cash flow in fiscal 2025.
How much operating cash flow does QGEN produce?
Operating cash flow was $654.33M, before capital expenditures of $201.05M.
Continue the stock analysis
Jump to another research area for this company.